Jiangsu Bioperfectus Technologies Co Ltd
688399
Company Profile
Business description
Jiangsu Bioperfectus Technologies Co Ltd is engaged in product development, production and sales of disease prevention and control, female genital micro-ecological testing and tumor screening. Its products portfolio includes Fever respiratory pathogen detection series, Fever with a rash pathogen test series, Fever with bleeding pathogen test series, Foodborne diseases and diarrheal pathogen detection and Other types of pathogen detection series.
Contact
3rd floor, Block G19, No.1 Yaocheng Avenue
Jiangsu
Taizhou
CHNT: +86 52386201616
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2025
Employees
592
Stocks News & Analysis
stocks
Market Minute: RBA cuts rates again, US CPI data released
This week, the RBA cut rates after a surprise hold in July; CBA reported earnings ; US inflation data came out, showing its highest reading since February.
stocks
Is the market still overlooking Alibaba’s AI potential?
Despite a 40% share price rally this year, investors could still be underestimating Alibaba’s cloud growth prospects.
stocks
ASX reporting season wrap: CBA, JB Hi-Fi, REA and more
A round up of notable stories and reactions as ASX earnings season gathers steam.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,212.10 | 63.00 | 0.69% |
| CAC 40 | 7,923.45 | 53.11 | 0.67% |
| DAX 40 | 24,359.30 | 18.20 | -0.07% |
| Dow JONES (US) | 44,946.12 | 34.86 | 0.08% |
| FTSE 100 | 9,138.90 | 38.34 | -0.42% |
| HKSE | 25,270.07 | 249.25 | -0.98% |
| NASDAQ | 21,622.98 | 87.69 | -0.40% |
| Nikkei 225 | 43,378.31 | 729.05 | 1.71% |
| NZX 50 Index | 12,889.38 | 55.30 | 0.43% |
| S&P 500 | 6,449.80 | 18.74 | -0.29% |
| S&P/ASX 200 | 8,938.60 | 64.80 | 0.73% |
| SSE Composite Index | 3,696.77 | 30.33 | 0.83% |